VBL to stop developing drug for psoriasis, ulcerative colitis
(Reuters) - Israel's VBL Therapeutics said it would stop developing its experimental inflammatory drug to fight psoriasis and ulcerative colitis, leading to half its market value being wiped off.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Health | Inflammatory Bowel Disease | Middle East Health | Psoriasis | Ulcerative Colitis